Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells

• Carmelo Carlo-Stella ,

  * E-mail: carmelo.carlostella@unimi.it

  Affiliations Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milano, Italy, Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy

  ⨯
• Silvia L. Locatelli,

  Affiliations Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milano, Italy, Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy

  ⨯
• Arianna Giacomini,

  Affiliations Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milano, Italy, Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy

  ⨯
• Loredana Cleris,

  Affiliation Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy

  ⨯
• Elena Saba,

  Affiliation Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy

  ⨯
• Marco Righi,

  Affiliation National Research Council, Institute of Neuroscience, Milan, Italy

  ⨯
• Anna Guidetti,

  Affiliations Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy, Department of Medical Physiopathology and Transplants, University of Milano, Milano, Italy

  ⨯
• Alessandro M. Gianni

  Affiliations Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy, Department of Medical Physiopathology and Transplants, University of Milano, Milano, Italy

  ⨯